Metabolic abnormalities caused by 3-acetylpyridine in the cerebral motor regions of rats: Partial recovery by thyrotropin-releasing hormone

Japanese Journal of Pharmacology

Volumn 82, Issue 4, 2000, Pages 295-300

  Kinoshita, Kiyoshi ^a   Watanabe, Yumi ^a   Asai, Hidetoshi ^a   Matsuoka, Yuzo ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

3 Acetylpyridine; Ataxia; Local cerebral glucose utilization; Taltirelin hydrate; Thyrotropin releasing hormone

Indexed keywords

3 ACETYLPYRIDINE; PROTIRELIN; TALTIRELIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATAXIA; BASAL GANGLION; BRAIN STEM; CONTROLLED STUDY; DRUG ANTAGONISM; GLUCOSE UTILIZATION; LIMBIC SYSTEM; MALE; NONHUMAN; RAT; SUBSTANTIA NIGRA; THALAMUS; VENTRAL TEGMENTUM;

EID: 0034023764     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.82.295     Document Type: Article

References (28)

1. Herken H: Functional disorders of the brain induced by synthesis of nucleotides containing 3-acetylpyridine. Z. Klin Chem Klin Biochem 6, 357-472 (1968)
2. Denk H, Haider M, Kovac W and Studynka G: Behavior changes and neuropathology 3-acetylpyridine poisoning in rats. Acta Neuropathol 10, 34-44 (1968)
3. Desclin JC and Escubi J: Effects of 3-acetylpyridine on the central nervous system of the rat, as demonstrated by silver method. Brain Res 77, 349-364 (1974)
4. Balaban CD: Central neurotoxic effects of intraperitoneally administered 3-acetylpyridine, harmaline and niacinamide in Sprague-Dawley and Long-Evans rats: a critical review of central 3-acetylpyridine toxicity. Brain Res Rev 9, 21-42 (1985)
5. Llinás R, Walton K and Hillman DE: Inferior olive: Its role in motor learning. Science 190, 1230-1231 (1975)
6. Bardin JM, Batini C, Billard JM, Buisseret-Delmas C, Conrath-Verrier M and Corvaja N: Cerebellar output regulation by the climbing and mossy fibers with and without the inferior olive. J Comp Neurol 213, 464-477 (1983)
7. Gibson GE and Blass JP: Oxdative metabolism and acetylcholine synthesis during acetylpyridine treatment. Neurochem Res 10, 453-467 (1985)
8. Griffiths EC: Clinical applications of thyrotropin-releasing hormone. Clin Sci 73, 449-457 (1986)
9. Horita A, Carino MA and Lai H: Pharmacology of thyrotropin-releasing hormone. Annu Rev Pharmacol Toxicol 26, 311-332 (1986)
10. O'Leary R and O'Connor B: Thyrotropin-releasing hormone. J Neurochem 65, 953-963 (1995)
11. Sobue I, Matsuoka Y, Katoh K and Sakuma A: TRH therapy of ataxia in patients with SCD. In TRH and Spinocerebellar Degeneration, Edited by Sobue I, pp 173-188, Elisevier, Amsterdam (1986)
12. Kinoshita K, Fujitsuka T, Yamamura T and Matsuoka Y: Effects of TA-0910, a novel orally active thyrotropin-releasing hormone analog, on the gait of ataxic animals. Eur J Pharmacol 274, 65-72 (1995)
13. Kinoshita K, Watanabe Y, Asai H, Yamamura M and Matsuoka Y: Anti-ataxic effects of TRH and its analogue, TA-0910, in Rolling mouse Nagoya by metabolic normalization of the central tegmental area. Br J Pharmacol 116, 3274-3278 (1995)
14. Kinoshita K, Watanabe Y, Yamamura M and Matsuoka Y: TRH receptor agonists ameliorate 3-acetylpyridine-induced ataxia through NMDA receptors in rats. Eur J Pharmacol 343, 129-133 (1998)
15. Pitts LH, Ross A, Chase GA and Faden AI: Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cords injuries. J Neurotrauma 12, 235-243 (1995)
16. Kanazawa I, Satoyoshi E, Hirayama K, Takayanagi T, Takahashi K, Kowa H, Tashiro K, Osame M, Shimizu N, Kachi T and Nakashima M: Clinical evaluation of taltirelin hydrate (TA-0910) in patients with spinocerebellar degeneration: A multi-center double-blind comparative study with placebo. J Clin Ther Med 13, 4169-4224 (1997)
17. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28, 897-916 (1977)
18. Sokoloff L, takahashi S, Gotoh J, Driscoll BF and Law MJ: Contribution of astroglia to functionally activated energy metabolism. Dev Neurosci 18, 344-352 (1996)
19. Watanabe Y, Kinoshita K, Koguchi A and Yamamura M: A new method for evaluation of motor deficits in 3-acetylpyridine-treated rats. J Neurosci Methods 77, 25-29 (1997)
20. Ogawa M, Araki M, Niijima K and Yoshida M: Microglial reactions in the inferior olive and its tract induced by intraperitoneal injection of 3-acetylpyridine in the rat. Neurodegeneration 1, 37-43 (1992)
21. Montarolo PG, Palestini M and Strata P: The inhibitory effect of the olivocerebellar input on the cerebellar Purkinje cells in the rat. J Physiol (Lond) 323, 187-202 (1982)
22. Benedetti F, Montarolo PG and Rabacchi S: Inferior olive lesion induces long-lasting functional modification in the Purkinje cells. Exp Brain Res 55, 368-371 (1984)
23. Benedetti F, Montarolo PG, Strata P and Tempia F: Inferior olive inactivation decreases the excitability of the intracerebellar and lateral vestibular nuclei in the rat. J Physiol (Lond) 340, 195-208 (1983)
24. Batini C, Billard JM and Daniel H: Long term modification of cerebellar inhibition after inferior olive degeneration. Exp Brain Res 59, 404-409 (1985)
25. Kinoshita K, Yamamura M, Sugihara J, Suzuki M and Matsuoka Y: Taltirelin hydrate (TA-0910): An orally active thyrotropn-releasing hormone mimetic agent with multiple actions. CNS Drug Rev 4, 25-41 (1998)
26. Chan-Palay V: Cerebellar Dentate Nucleus: Organization, Cytology and Transmitters, Springer-Verlag, Berlin (1977)
27. Perciavalle V, Berretta S and Raffaele R: Projections from the intracerebellar nuclei to the ventral midbrain tegmentum in the rat. Neuroscience 29, 109-119 (1989)
28. Ruigrok TJH and Cella F: Precerebellar nuclei and red nucleus. In The Rat Nervous System, Edited by Paxonos G, pp 277-308, Academic Press, Sydney (1995)